Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Type II JAK2 Inhibitor Gets Off to a Strong Start.

Cancer discovery·2026
Same journal

Pancreatic Cancer: Translating Tumor Biology into Actionability.

Cancer discovery·2026
Same journal

Reconsidering Cancer Therapy through the Lens of Biomolecular Condensates.

Cancer discovery·2026
Same journal

The Promise of Machine Learning-Based Population Screening for Hepatocellular Carcinoma.

Cancer discovery·2026
Same journal

Spatially Resolved Proteomic Cartography Illuminates the Earliest Molecular Programs in Pancreatic Cancer Evolution.

Cancer discovery·2026
Same journal

Oral Regimens for AML Make Strides.

Cancer discovery·2026
See all related articles

Related Experiment Video

Updated: Mar 18, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Enhancing PD-1 Blockade in Solid Tumors

    Cancer Discovery
    |July 3, 2016
    PubMed
    Summary
    This summary is machine-generated.

    This Phase I trial shows that combining utomilumab with pembrolizumab is safe for various solid cancers. The treatment combination demonstrated sustained patient responses, indicating potential therapeutic benefits.

    More Related Videos

    Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
    06:07

    Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

    Published on: February 5, 2020

    6.2K
    Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
    10:11

    Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

    Published on: January 3, 2013

    23.6K

    Related Experiment Videos

    Last Updated: Mar 18, 2026

    Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
    07:04

    Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

    Published on: May 2, 2025

    1.3K
    Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
    06:07

    Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

    Published on: February 5, 2020

    6.2K
    Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
    10:11

    Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

    Published on: January 3, 2013

    23.6K

    Area of Science:

    • Oncology
    • Immunotherapy
    • Clinical Trials

    Background:

    • The study investigates the safety and efficacy of combining utomilumab, a CD137-binding antibody, with pembrolizumab in patients with advanced solid tumors.
    • CD137 agonism is a promising immunotherapy strategy to enhance anti-tumor immune responses.
    • Pembrolizumab, an immune checkpoint inhibitor, has shown efficacy in various cancers.

    Framework:

    • This was a Phase I clinical study designed to assess the safety, tolerability, and preliminary efficacy of the combination therapy.
    • The study enrolled patients with diverse solid malignancies who had progressed on or were intolerant to standard therapies.
    • Dose escalation and expansion cohorts were utilized to determine the maximum tolerated dose and recommended Phase II dose.

    Implementation:

    • Patients received escalating doses of utomilumab in combination with a standard dose of pembrolizumab.
    • Safety endpoints included the incidence of adverse events, dose-limiting toxicities, and laboratory abnormalities.
    • Efficacy was assessed through objective response rates, duration of response, and progression-free survival.

    Implications:

    • The combination of utomilumab and pembrolizumab was found to be safe and well-tolerated in patients with various solid cancers.
    • Sustained clinical responses were observed, suggesting potential synergistic activity between CD137 agonism and PD-1 blockade.
    • These findings support further investigation of this combination in Phase II/III trials for specific solid tumor indications.